Acute Myeloid Leukemia Market Report 2026

Acute Myeloid Leukemia Market Overview

• Acute Myeloid Leukemia market size has reached to $3.73 billion in 2025 • Expected to grow to $5.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Rising Adoption Of Personalized Medicine To Drive Market Growth • Market Trend: Pharmaceutical Companies Enhancing Acute Myeloid Leukemia Treatment Armamentarium With Quizartinib Approval • North America was the largest region in 2025.

What Is Covered Under Acute Myeloid Leukemia Market?

Acute myeloid leukemia (AML) is a type of blood cancer that occurs due to abnormal white blood cell in bone marrow. Myeloblasts, also known as leukemic blasts, or excessive production of immature white blood cells, are the hallmark of AML. The bone marrow is crowded with these cells, which stops it from producing healthy blood cells. The main acute myeloid leukemia treatment types include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy. Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cells in the body. The different acute myeloid leukemia chemotherapies include cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, and hormonal therapy. They are of various regimens such as DC regimen, AVD regimen, and VCD regimen. Acute myeloid leukemia is treated by different end-users such as hospitals, retail drug stores, ambulatory care centers, and clinics.

What Is The Acute Myeloid Leukemia Market Growth Forecast?

The acute myeloid leukemia market size is expected to see strong growth in the next few years. It will grow to $5.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to advancement in targeted therapy drugs, increasing stem cell transplant procedures, development of novel tyrosine kinase inhibitors, expansion of ambulatory care centers, integration of personalized medicine approaches in treatment. Major trends in the forecast period include increasing adoption of targeted aml therapies, rising use of stem cell transplantation procedures, growing demand for personalized chemotherapy regimens, expansion of tyrosine kinase inhibitors and monoclonal antibodies, enhanced focus on early diagnosis and aml monitoring.

Global Acute Myeloid Leukemia Market Segmentation

1) By Treatment Type: Chemotherapy, Stem Cell Transplant, Targeted Therapy 2) By Treatment Phase: Induction Therapy, Consolidation Therapy, Maintenance Therapy, Relapsed Or Refractory Therapy 3) By End-User: Hospitals, Specialty Oncology Centers, Transplant Centers, Research and Academic Institutes Subsegments: 1) By Chemotherapy: Cytarabine-Based Therapy, Anthracycline-Based Therapy, Hypomethylating Agents, Low-Intensity Chemotherapy, Combination Chemotherapy Regimens 2) By Stem Cell Transplant: Allogeneic Stem Cell Transplant, Autologous Stem Cell Transplant, Conditioning Regimens, Post-Transplant Maintenance Therapy 3) By Targeted Therapy: FLT3 Inhibitors, IDH1 Inhibitors, IDH2 Inhibitors, BCL-2 Inhibitors, Hedgehog Pathway Inhibitors, Monoclonal Antibodies, Other Targeted Agents

What Is The Driver Of The Acute Myeloid Leukemia Market?

The increasing adoption of personalized medicine is expected to propel the growth of the acute myeloid leukemia market going forward. Personalized medicine is an innovative approach to medical treatment and healthcare that considers individual differences in patients' genes, environments, and lifestyles. In acute myeloid leukemia (AML), personalized medicine is employed through molecular profiling to identify specific genetic mutations and biomarkers unique to individual patients. This information guides the selection of targeted therapies and tailored treatment plans, optimizing the effectiveness of interventions while minimizing adverse effects for a more personalized and precise approach to AML management. For instance, in February 2024, according to the Personalised Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the increasing adoption of personalized medicine is driving the growth of the acute myeloid leukemia industry.

Key Players In The Global Acute Myeloid Leukemia Market

Major companies operating in the acute myeloid leukemia market are Pfizer Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Servier Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Agios Pharmaceuticals Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Genmab AS, Aptose Biosciences Inc., Daiichi Sankyo Company Limited, BeiGene Ltd., Jazz Pharmaceuticals plc, Ipsen S.A.

Global Acute Myeloid Leukemia Market Trends and Insights

Major companies operating in the acute myeloid leukemia market are focused on developing advanced drug solutions, such as maintenance monotherapy, to expand their product portfolios to improve patient outcomes and address unmet medical needs. Maintenance monotherapy refers to a medical treatment approach where a single therapeutic agent is administered to a patient as an ongoing, long-term therapy to prevent the recurrence or progression of a medical condition. For instance, in July 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, received United States Food and Drug Administration (USFDA) approval for quizartinib (Vanflyta) in combination with standard cytarabine and anthracycline induction, followed by cytarabine consolidation, and as maintenance monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults with FLT3 internal tandem duplication (ITD)-positive status, as determined by an FDA-approved test. The LeukoStrat CDx FLT3 Mutation Assay has also been approved as a companion diagnostic for Vanflyta. The approval is based on positive results from the QuANTUM-First trial, showing a statistically significant improvement in overall survival for patients receiving quizartinib compared to a placebo. Quizartinib's recommended dosage varies during induction, consolidation, and maintenance phases. The drug is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation.

What Are Latest Mergers And Acquisitions In The Acute Myeloid Leukemia Market?

In March 2023, QIAGEN, a Netherlands-based biotechnology company, partnered with Servier Laboratories, for an undisclosed amount. This partnership aims to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor intended for treating acute myeloid leukemia (AML). Under this Master Collaboration Agreement, QIAGEN will create and validate a real-time in vitro PCR test designed to detect IDH1 gene mutations in AML patients using blood and bone marrow samples. This collaboration enhances the global accessibility of TIBSOVO for AML patients with IDH1 mutations and reinforces QIAGEN's role in developing companion diagnostics for emerging biomarkers in onco-hematology, furthering precision medicine initiatives. Servier Laboratories, a France-based pharmaceutical company.

Regional Outlook

North America was the largest region in the acute myeloid leukemia market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Myeloid Leukemia Market?

The acute myeloid leukemia market includes revenue earned by drugs such as DC regimen, AVD Regimen, VCD regimen, cytarabine, vidaza, dacogen, midostaurin, quizartinib, vosaroxin that are used for the treatment of acute myeloid leukemia. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acute Myeloid Leukemia Market Report 2026?

The acute myeloid leukemia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acute myeloid leukemia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.